Universal Biosensors gets second $1.5m payment
27 July, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) has earned a second $1.5 million milestone payment from Siemens Healthcare, seven weeks after receiving the first.
AAMRI calls for government to spur biotech commercialisation
27 July, 2012 by Tim DeanThe government has a significant role to play in helping Australia’s world class medical research be translated into genuine health and economic benefits, says the Association of Australian Medical Research Institutes (AAMRI).
Investment event of the year calls for expressions of interest
26 July, 2012 by AusBiotechAusBiotech invites your expression of interest for the opportunity to present at the Australasian Life Science Investment Summit (ALSIS) 2012 as one of 40 of Australasia’s most promising biotechnology companies.
BREVAGen receives approval to sell in California
26 July, 2012 by Tim DeanGenetic Technologies (ASX:GTG) continues its push into the US with BREVAGen, with it gaining approval to sell into California.
CoDa raises NZ$25m to fund wound treatment
26 July, 2012 by Dylan Bushell-EmblingNZ biotech CoDa Therapeutics has received a NZ$24.5 million funding injection from a Russian investor, to help continue commercialisation of wound therapy Nexagon.
Mesoblast eyes human trials of stem cell treatment for rheumatoid arthritis
25 July, 2012 by Dylan Bushell-EmblingAnimal trials of Mesoblast's (ASX:MSB) mesenchymal stem cells in rheumatoid arthritis (RA) have encouraged the company press on with an FDA application for a phase II trial.
AtCor files FDA application for cardiovascular monitor
25 July, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has submitted an application for approval to market its updated SphygmoCor XCEL cardiovascular monitoring system in the US.
Positive results from C-Pulse follow-up
25 July, 2012 by Dylan Bushell-EmblingSunshine Heart (ASX:SHC) has released promising 12-month follow-up data from the feasibility trial for its C-Pulse Heart Assist System, as the trial heads into the two-year follow-up stage.
Bioniche canine cancer product approved in NA
25 July, 2012 by Dylan Bushell-EmblingUS and Canadian regulators have approved Immunocidin, the first of two canine cancer products developed by Bioniche (ASX:BNC).
AusIndustry to hold registration workshops on Tax Incentive
24 July, 2012 by AusBiotechAusIndustry is holding registration ready workshops to help companies better understand and register for the R&D Tax Incentive.
pSivida gets FDA nod for phase III Medidur trial
23 July, 2012 by Dylan Bushell-EmblingThe FDA has cleared pSivida (ASX:PVA) to jump straight to phase III trials of its micro-insert to deliver a posterior uveitis treatment, and to cite partner Alimera's data in its IND application.
Narhex ex-CEO licenses HIV treatment for Mexico
23 July, 2012 by Dylan Bushell-EmblingNarhex (ASX:NLS) founder and former CEO John Majewski will form a new company to register and commercialise a HIV treatment developed under his watch in the Mexican market.
Feature: Banking on nature
23 July, 2012 by Graeme O'NeillThe Eskitis Institute’s Nature Bank holds a huge array of natural compounds for screening as potential drug leads, and researchers have invented a revolutionary new mass spectrometry tool to detect binding reactions with molecular targets.
Iluvien on the march in Europe
20 July, 2012 by Tim DeanpSivida (ASX:PVA) has had two wins this week for Iluvien, its treatment for vision impairment associated with chronic diabetic macular edema (DME).
BioDiem partners with RMIT to extend vaccine technology
20 July, 2012 by Tim DeanBioDiem (ASX:BDM) is looking to develop its vaccine technology to target indications beyond influenza through a research partnership with RMIT.
